Every DEA registrant that handles Schedule II through V controlled substances must complete a biennial inventory at least every two years, and the count is one of the first records a DEA diversion investigator checks on inspection. The requirement sits in 21 CFR 1304.11, and it is more than a single due date. The rule sets an initial inventory obligation, a two-year repeat cycle, a counting method that changes by schedule, and a retention period, and a pharmacy that gets any one piece wrong has created a documented gap before an investigator opens a single dispensing log.
When the Biennial Inventory Is Due
The clock starts with the initial inventory, taken on the date the pharmacy first engages in the manufacture, distribution, or dispensing of controlled substances. After that, 21 CFR 1304.11(c) requires a new inventory of all controlled substances on hand at least every two years. The regulation does not fix one calendar date for every pharmacy: the biennial inventory may be taken on any date within two years of the previous biennial inventory date, which lets a pharmacy move its count to a slower week without falling out of compliance. Each inventory record must state the date it was taken and whether the count was made as of the opening or the close of business that day, a detail auditors check against the pharmacy's own inventory reconciliation records.
Exact Counts Versus Estimates by Schedule
The counting method depends on the schedule, and the regulation does not let a pharmacy pick whichever is easier. Schedule I and Schedule II substances always require an exact count or measure of the contents, opened container or not. There is no estimate allowed for Schedule II product, which covers the highest-volume diversion targets in most pharmacies, including oxycodone, hydrocodone combination products, and prescription stimulants. Schedule III, IV, and V substances may be estimated, with one exception written directly into the rule: once an opened container holds more than 1,000 tablets or capsules, the pharmacy must count it exactly rather than estimate. A pharmacy that eyeballs a large, opened bottle of a Schedule III product because the count looks close enough has violated the counting rule regardless of whether the final number happens to be correct.
A biennial inventory count is rarely just a paperwork exercise. It is the reference point a DEA investigator uses to test every dispensing record that follows.
Retention and What Happens if the Count Is Wrong
21 CFR 1304.04 requires every inventory and controlled substance record to be kept for at least two years from the date of the inventory, available for inspection and copying by DEA personnel. Schedule I and II inventories and records must be maintained separately from the rest of the pharmacy's records; Schedule III, IV, and V records can be kept separately or folded into ordinary business records, as long as the controlled substance information stays readily retrievable. An inventory discrepancy found during a DEA inspection rarely stays isolated. Investigators treat a shortfall as the starting point for a broader review of dispensing records, and in cases involving suspected diversion, that review can escalate toward a DEA order to show cause or, in the most severe cases, an immediate suspension order before the pharmacy has time to explain the count.
A pharmacy that keeps its inventory records inside the same audit-ready system it uses for ordering and dispensing records has a defensible answer ready before the question is asked. The broader recordkeeping standard the biennial inventory feeds into is covered in DEA Recordkeeping: The Audit-Ready Controlled Substance File.
Why Early Legal Counsel Is Critical
It is critical that pharmacies promptly retain experienced healthcare defense counsel upon receiving a DEA inspection notice, an inventory discrepancy finding, or any other government inquiry involving controlled substances. Early legal intervention can protect the pharmacy's rights, ensure appropriate responses to DEA requests, avoid inadvertent admissions, preserve relevant defenses, and allow counsel to communicate with investigators on the pharmacy's behalf. Delaying legal representation can significantly affect the outcome of a matter, particularly once an inventory shortfall is used to justify a broader review of dispensing records.
How Health Law Alliance Can Help
Health Law Alliance defends pharmacies and DEA registrants through inspections, inventory discrepancy findings, and registration actions as part of the firm's DEA defense practice. Our team reviews a pharmacy's inventory records and counting methodology against the same standard a diversion investigator applies, so a discrepancy gets corrected before it becomes a governmental finding. If your pharmacy has an inventory question, has received an inspection notice, or wants its biennial inventory records reviewed before the count is due, contact us for a free, confidential consultation.
